SCHEMBL327753

SCHEMBL327753

CCCn1c(=O)[nH]c2ccc(C(=O)c3ncc4ccccn34)cc2c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.41
ALDH1A1 P00352 6/20 0.41
HSD17B10 Q99714 5/20 0.41
GAA P10253 4/20 0.41
HPGD P15428 4/20 0.41
ADORA3 P0DMS8 1/20 0.41
ADORA2B P29275 1/20 0.41
ADORA1 P30542 1/20 0.41
POLB P06746 2/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
HTR3A P46098 1/20 0.39
NPC1 O15118 1/20 0.38
HTT P42858 1/20 0.38
CYP1A2 P05177 1/20 0.37
RAB9A P51151 1/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17074451 0.89 KDM4E (0.39) KDM4EALDH1A1HSD17B10GAAHPGD
SCHEMBL14927289 0.87 ADORA3 (0.43) KDM4EALDH1A1HSD17B10HPGDADORA3
SCHEMBL321649 0.87 KDM4E (0.48) KDM4EALDH1A1HSD17B10GAAHPGD
SCHEMBL17074452 0.82 KDM4E (0.39) KDM4EALDH1A1HSD17B10GAAHPGD
SCHEMBL322579 0.81 NPC1 (0.41) KDM4EALDH1A1HSD17B10GAAHPGD
SCHEMBL323368 0.81 NPC1 (0.43) KDM4EALDH1A1HSD17B10GAAHPGD
SCHEMBL323012 0.80 KDM4E (0.42) KDM4EALDH1A1HSD17B10GAAHPGD
SCHEMBL14917192 0.79 ALDH1A1 (0.41) KDM4EALDH1A1HSD17B10GAAHPGD
SCHEMBL322448 0.77 GAA (0.39) KDM4EALDH1A1HSD17B10GAAHPGD
SCHEMBL323013 0.77 KDM4E (0.37) KDM4EALDH1A1HSD17B10GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590976-B1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-09-16 EP claimed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 US claimed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US claimed
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 US disclosed
US-9452164-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2016-09-27 US disclosed
EP-2800566-B1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI SA (FR) 2015-10-28 EP disclosed
EP-2590976-B1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-09-16 EP disclosed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 US disclosed
EP-2800566-A1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI (FR) 2014-11-12 EP disclosed
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-28 US disclosed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 US disclosed
WO-2013102860-A1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI (FR) 2013-07-11 WO disclosed
EP-2590976-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 EP disclosed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004732-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH KDM4E 728/4885ALDH1A1 2306/4885HSD17B10 4532/4885
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives CCNY, UTS2R, WNK2 KDM4E 468/4885ALDH1A1 2378/4885HSD17B10 4646/4885
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH KDM4E 728/4885ALDH1A1 2306/4885HSD17B10 4532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.